You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

934 Results
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Oct 2020
Regimen
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Jun 2019
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Document
Document
Document

Pages